VenoStent (YC S20) — Absorbable wrap for blood vessels
There are 10 million dialysis and bypass surgeries per year, but half of them fail. VenoStent saves lives with a wrap that goes around blood vessels during surgery so they don't fail.
VenoStent is a Y Combinator company in the Summer 2020 batch. Its directory entry describes it as: Absorbable wrap for blood vessels. The founders listed are Tim Boire (Founder), Geoffrey Lucks (Founder) (Y Combinator directory entry, June 29, 2020).
Get an email when VenoStent changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
There are 10 million dialysis and bypass surgeries per year, but half of them fail. VenoStent saves lives with a wrap that goes around blood vessels during surgery so they don't fail.
Checked away from the directory entry. What is below does not come from the company's Y Combinator page.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Tim Boire
Founder
President and CEO of VenoStent, Inc. I developed these novel smart polymeric biomaterials for vascular applications during my PhD at Vanderbilt University. Focus of the technology shifted to hemodialysis access applications after participating in the 2014 NSF I-Corps program. BS, Chemical & Biological Engineering and Biotechnology, Tufts University, 2008; PhD, Biomedical Engineering, Vanderbilt University, 2017. Worked in R&D at Genzyme Corporation, 2008 - 2011. Grew up in Nashua, NH.
Geoffrey Lucks
Founder
Co-founder & COO of pivotal trial-stage therapeutic medical device company developing bioabsorbable wraps to improve vascular surgery. Vandy MBA, UPenn Masters of Bioethics, UW-Madison UG
Interested in tech and culture. Reading: the classics, religion, economics, finance, politics, philosophy, history, social sciences, etc. Born mellow and everywhere harshed.
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
One of 44 companies held here in Healthcare › Medical Devices.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Want the whole picture on VenoStent?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on VenoStent: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on VenoStent covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind VenoStent: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
